Celldex Therapeutics
CLDX
130 hedge funds and large institutions have $645M invested in Celldex Therapeutics in 2020 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 33 increasing their positions, 24 reducing their positions, and 13 closing their positions.
308% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 13
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more funds holding
Funds holding: 91 → 130 (+39)
38% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $8.52M
38% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 24
35% more capital invested
Capital invested by funds: $477M → $645M (+$168M)
11.99% more ownership
Funds ownership: 81.05% → 93.04% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$32.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.7M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$24M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$18.5M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$45.5M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$17.8M |
| 3 |
Renaissance Technologies
New York
|
-$12.4M |
| 4 |
O
OrbiMed
New York
|
-$9.27M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$7.93M |
CLDX Hedge Fund Activity: Q4 2020 in Review
130 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2020, worth a combined $645M — up 35% from $477M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new CLDX positions and 13 closed out — a net gain of 40 holders — while 33 added to existing stakes and 24 trimmed.
The largest buyer was State Street, adding an estimated $32.1M. The largest seller was BVF Inc, exiting entirely with an estimated $45.5M sold.
- 130 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2020, up from 91 in Q3 2020.
- Funds reported $645M of Celldex Therapeutics stock for Q4 2020, up 35% quarter-over-quarter.
- 53 funds opened new Celldex Therapeutics positions in Q4 2020 and 13 closed out, a net change of +40 holders.
- The largest Celldex Therapeutics buyer in Q4 2020 was State Street, an estimated $32.1M added.
- The largest Celldex Therapeutics seller in Q4 2020 was BVF Inc, an estimated $45.5M sold.
Based on aggregated 13F filings for Q4 2020.